Evidence map›Paper›PMID 38597968›Full record

ReviewHNO2024

[Importance of aspirin challenges in patients with NSAID-exacerbated respiratory disease].

Ulrike Förster-Ruhrmann, Heidi Olze

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in HNO, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ulrike Förster-RuhrmannHNO-Klinik, Charité - Universitätsmedizin Berlin (CCM/CVK), Charitéplatz 1, 10117, Berlin, Deutschland. ulrike.foerster@charite.de.
Heidi OlzeHNO-Klinik, Charité - Universitätsmedizin Berlin (CCM/CVK), Charitéplatz 1, 10117, Berlin, Deutschland.
Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is often characterized by a severe course of chronic rhinosinusitis with nasal polyps (CRSwNP), comorbid asthma, and NSAID hypersensitivity. The gold standard for N-ERD diagnosis is challenge with acetylsalicylic acid (ASA). In expert recommendations, the diagnosis of N-ERD is established based on a plausible positive history of NSAID hypersensitivity and CRSwNP with asthma.

objectiveThe following review describes the performance of ASA challenges and their sensitivity and specificity. It also examines the extent to which a positive history of NSAID hypersensitivity correlates with ASA challenge results in clinical trials and when ASA challenges should be performed. RESULTS AND

conclusionASA challenges have high sensitivity and specificity. In clinical ASA challenge studies, there is a high concordance between a positive history of NSAID hypersensitivity obtained by rhinologists and the measured data of ASA challenge in patients with CRSwNP and comorbid asthma. Therefore, ASA challenge is primarily indicated in patients with an unclear history of NSAID hypersensitivity.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalAspirinAsthma, Aspirin-InducedBronchial Provocation TestsDrug HypersensitivityEvidence-Based MedicineHumansNasal Provocation TestsReproducibility of ResultsRhinitisSensitivity and SpecificitySinusitisAnti-Inflammatory Agents, Non-SteroidalAspirinAngioedemaNasal polypsNSAID-induced asthmaRhinitisSensitivity and specificity

Identifiers

PMID38597968
OpenAlexW4394679660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.